

Table 1. Summary of lipid data for LANTUS (from 4002 Study) and AMARYL (from two AMARYL studies with placebo control)

Variable	Subgroup by TG baseline range	Sample size	Treatment	Baseline	Endpoint	Change at Endpoint (Mean(SD))	% reduction from baseline	LANTUS - AMARYL
Triglycerides	300-500	44	LANTUS	362	240	-122.5(102)	34%	52.5
		50	AMARYL	390	321	-70.0(111)	18%	
	500-1000	25	LANTUS	661	409	-252.0(208)	38%	34.4
		16	AMARYL	662	445	-217.6(188)	33%	
	300-1000	69	LANTUS	470	301	-169.4(160)	36%	63.6
		66	AMARYL	459	350	-105.8(147)	23%	
Non-HDL Cholesterol	200-500	124	LANTUS	288	232	-56.3(117)	25%	21.7
		129	AMARYL	299	265	-34.6(107)	12%	
	300-500	44	LANTUS	180	152	-27.6(56)	15%	21.9
		30	AMARYL	203	198	-5.7(32)	3%	
	500-1000	25	LANTUS	186	171	-14.1(35)	8%	-9.0
		16	AMARYL	224	200	-23.1(35)	10%	
HDL	300-1000	69	LANTUS	181	163	-18.5(40)	10%	8.6
		66	AMARYL	209	198	-9.9(33)	5%	
	200-500	124	LANTUS	167	135	-12.3(33)	7%	5.8
		129	AMARYL	197	191	-6.7(30)	4%	
	300-500	44	LANTUS	40	40	0.1(6)	3%	
		50	AMARYL	36	37	1.2(6)		
LDL	500-1000	25	LANTUS	33	36	3.1(7)		
		16	AMARYL	37	39	1.6(6)		
	300-1000	69	LANTUS	37	38	1.2(7)		
		66	AMARYL	36	37	1.3(6)		
	200-500	124	LANTUS	42	41	-0.6(8)		
		129	AMARYL	38	39	1.2(5)		
LDL	All	306	LANTUS	113	110	-3.3(27)		
		272	AMARYL	142	140	-1.5(23)		